VICO Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
VO659 / VICO Therap
2022-001314-19: A first-in-human trial to test how safe a new drug called VO659 is for people with genetic disorders called spinocerebellar ataxia type 1, 3 or Huntington’s disease

Ongoing
1/2
95
Europe
VO659, VO659, Solution for injection
VICO Therapeutics B.V., VICO Therapeutics B.V.
spinocerebellar ataxia types 1, 3 and Huntington’s disease, spinocerebellar ataxia types 1 or 3 and Huntington’s disease, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05822908 / 2022-001314-19: A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

Recruiting
1/2
65
Europe, RoW
VO659
Vico Therapeutics B. V., VICO Therapeutics B.V.
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
09/25
09/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
VO659 / VICO Therap
2022-001314-19: A first-in-human trial to test how safe a new drug called VO659 is for people with genetic disorders called spinocerebellar ataxia type 1, 3 or Huntington’s disease

Ongoing
1/2
95
Europe
VO659, VO659, Solution for injection
VICO Therapeutics B.V., VICO Therapeutics B.V.
spinocerebellar ataxia types 1, 3 and Huntington’s disease, spinocerebellar ataxia types 1 or 3 and Huntington’s disease, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05822908 / 2022-001314-19: A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

Recruiting
1/2
65
Europe, RoW
VO659
Vico Therapeutics B. V., VICO Therapeutics B.V.
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
09/25
09/25

Download Options